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Ab~tract: The pharmacokinetics of cyclosporine were studied in five liver transplant 
patients when they were on and off hemodialysis. There was no significant difference 
In the blood clearance of cyclosporine between these two periods. Less than 1 per cent 
of the dose of cyclosporine was recovered in the dialysate. The mean dialysis clear-
ance was less than 1 ml/min. This represents less than 1 per cent of the total blood 
clearance of cyclosporine. Dosage alterations of cyclospori ne during or after hemod i-
alysis do not appear to be necessary. . 
CYCLOSPORINE is a cyclic undecapeptide 
of fungal origin with significant im-
munosuppressant activity.l Cyclosporine 
and prednisone are the primary immuno-
suppressive agents used in the recipients of 
transplan ted kidneys, livers, hearts, heart-
lungs, and bone marrow.2- S Kidney trans-
plant recipients may require temporary 
hemodialysis due to acute tubular necrosis 
which occurs in 12 to 40 per cent of these 
patients.5•7 At our institution, approxi-
mately 10 per cent of liver transplant recip-
ients require hemodialysis due to surgical 
complications or drug-induced toxicity. 
Hemodialysis is known to increase the 
clearance of certain drugs.s This study was 
undertaken to determine the extent to 
which cyclosporine is removed by hemodi-
alysis and to predict whether cyclosporine 
dose supplements are necessary for pa-
tients after dialysis. This information is of 
importance since it is generally felt that the 
success of an organ transplant is closely 
related to optimal early immunosuppres-
sion. 
From the Clinical Pharmacokinetics Laboratory, Uni· 
versity of Pittsburgh. School of Pharmacy, and the De-
partments of Medicine and Sur!!ery. School of Medicine, 
Pittsburgh. Penn. 15261. 
Methods 
Five adult recipients of transplanted 
livers were studied. All patients required 
hemodialysis to manage postoperative 
renal failure. Patients were dialyzed with a 
Gambro 17 dialyzer (Gambro Inc., Newport 
News, Va_) (surface area 1.02 m2, mem-
brane thickness 17 iJ.) for 4 hours. All pa-
tients received cyclosporine (Sandoz Phar-
maceuticals, East Hanover, N.J.) by in-
travenous infusion over 1 to 1.5 hours, The 
cyclosporine doses ranged from 100 to 200 
mg administered at 8-hourintervals. Hourly 
venous blood samples were obtained during 
the dosing interval prior to dialysis and 
during the next dosing interval in which 
the patient was dialyzed. Blood samples 
were stored at -20°C until analysis, 
Dialysate (Eri-Lyte 8336; Erika Inc" 
Rock Leigh, N.J.) was collected from four of 
the patients and analyzed for cyclosporine. 
Aliquots (100 to 300 ml) of dialysate were 
lyophylized to 10 to 15 ml prior to extraction 
using a freeze dryer (Virtis Company, Inc" 
Gardiner, N,Y,)' Blood and dialysate were ex-
tracted using the procedure of Sawchuck 
and Cartier," Samples were analyzed by 
high-pressure liquid chromatography. us-
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TABLE I 
Cyclosporine Clearance Off and On Dialysis 
Patient no. 
Clearance off dialysis 
(mllmin) 
Clearance on dialysis 
(mllminl 
2 
3 
4 
5 
Mean ± S.D. 
* P> 0.10 by paired t·test. 
483 
536 
506 
324 
463 ± 95 
ing a 25-cm, 5f..(, C 1H column (Supelco, Belle-
fonte, Penn.) heated to 70°C and by ultravi-
olet detection (Model 441, Waters Assoc., 
Milford, Mass.) at 214 nm. Standards were 
prepared in blank blood and dialysate, and 
the internal standard was cyclosporin D 
(Sandoz Pharmaceuticals, Basel, Switzer· 
land). The mobile phase was acetonitrile: 
water (68.5:31.5) delivered at 1.8 mllmin. 
Under these conditions, the retention time 
was 9.8 minutes for cyclosporine and 12.8 
minutes for cyclosporin D. 
The total body clearance of cyclosporine 
was calculated on and off dialysis by 
dose 
clearance = ----
AUC(O-r) 
(1) 
where AUC(O = r)isthe area under the blood 
concentration-time curve over the dosing 
interval r studied. 
337 
385 
518 
353 
398 ± 82* 
The dialysis clearance was calculated 
from 
R 
dialysis clearance (2) 
AUC(O-t) 
where R is the total amount of solute re-
covered in the dialysate and AUC(O-t) is 
the area under the blood concentration-
time curve over the period of dialysis (t). 
The significance of the difference between 
the total body clearance of cyclosporine on 
and off dialysis was analyzed by a paired 
t-test. 
Results 
The standard curve for the estimation of 
cyclosporine was linear over a concentra-
tion range of 50 to 2000 ng/ml. The coeffi-
cient of variation of the analytical method 
was 3.95 per cent at 600 ng/ml (N = 10). No 
TABLE II 
Dialysis Clearance of Cyclosporine 
Dose ofiv 
cyclosporine 
Patient no. (mg) 
1 150 
2 150 
3 140 
4 200 
Mean ± S.D. 
November·December lflK.j 
Dialysate 
volume (liters) 
48 
37 
38 
54 
Amount of 
cyciosporine in 
dialysate (I'g) 
31.8 
ILl 
5.1 
19.7 
16.9 ± 11.6 
Dialysis 
clearance 
(mllminl 
1.068 
0.072 
0.021 
0.057 
0.305 ± 0.509 
529 
VENKATARAMANAN, PTACHCINSKI, BURCKART, ET AL. 
TABLE III 
Arterial and Venous Cyclosporine 
Blood Concentrations 
Sample no. 
1 
2 
3 
4 
5 
6 
7 
Cyclosporine concentration 
(ng/ml)* 
Arterial Venous 
259 259 
432 491 
353 213 
2143 2203 
1343 1231 
736 991 
610 552 
• P> 0.10 by paired t-test. 
significant difference was observed in the 
blood concentration-time curves of patients 
on or off dialysis. The total body clearance 
of cyclosporine while on dialysis was not 
significantly different (P > 0.10) from the 
clearance off dialysis (Table I).Two of the 
four patients studied had a decrease in total 
body clearance during the dosing interval 
on dialysis. Patient 1 was not included in 
this comparison since blood samples were 
obtained from this patient only before, 
after, and at the midpoint of dialysis. 
Very little cyclosporine was recovered 
from the dialysate of the patients studied 
(mean 16.9 J.I.g). The mean dialysis clear-
ance was determined to be 0.305 ± 0.509 
mllmin (Table II). 
In one patient (N o. 3), arterial and venous 
blood samples were obtained during two 
dialysis periods (total of seven samples) 
and analyzed for cyclosporine to determine 
if a difference might be observed. There 
was no statistical difference (P > 0.10) 
between arterial and venous concentrations 
of cyclosporine when analyzed by a paired 
t-test (Table III). 
Discussion 
The present studies were carried out at 
steady state over one dosing interval. The 
relatively smaller dosing interval (8 hours) 
with reference to the half-life of the drug 
530 
(t1.2 = 6.4 to 27 hours)lO precluded calcula-
tion of pharmacokinetic parameters other 
than the clearance of the drug. 
The total body clearance of cyclosporine 
for patients being dialyzed did not differ 
significantly (P > 0.10) from the clearance 
w hen the patients were not being dialyzed. 
The lower clearance of cyclosporine in two 
patients during dialysis may be due to 
diurnal variations in clearance that have 
been observed in several of our patients 
studied (unpublished observations). The 
clearance of cyclosporine appears to be 
lower during the day (patients were dia-
lyzed during the day). compared to at night. 
The mean dialysis clearance was 0.305 
ml/min for all patients studied. Excluding 
patient 1, whose dialysis clearance was 
considerably higher than the other three 
patients studied, the mean dialysis clear-
ance was 0.050 ± 0.026 mllmin. Patient 1 
had a much higher dialysis clearance than 
the other patients studied. Her dose was 
similar to the other patients, and all doses 
were given by the intravenous route. The 
actual reasons for such a difference in the 
dialysis clearance is not known. However, 
the difference observed in the dialysis 
clearance in this patient does not alter the 
conclusion that dialysis clearance repre-
sents less than 1 per cent of the total body 
clearance. 
Cyclosporine is not significantly removed 
from the body by hemodialysis. The resul ts 
are explained by the fact that cyclosporine 
is only minimally eliminated by the kid-
neys, has a high molecular weight (1202), is 
highly lipid soluble, is significantly bound 
to plasma lipoproteins, and has a large 
volume of distribution. II- 13 These factors 
are all known to influence the dialyzability 
of drugs. Hl5 No difference was observed 
between the concentration of cyclosporine 
in arterial and venous blood samples. This 
indicates that very little cyclosporine 
passed through the dialyzer membrane. 
Substantial differences in dialysis clear-
ance have been observed among different 
dialyzers.' Only one dialyzer type was used 
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in our study, but little difference would be 
expected in the dialysis clearance of cyc-
losporine among dialyzers, The process of 
hemodialysis does not significantly affect 
the total body clearance of cyclosporine, 
and dosage alteration of cyclosporine dur-
ing or after hemodialysis is not necessary. 
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